Agios Pharmaceuticals Inc. (AGIO) Lowered to Sell at Zacks Investment Research
Agios Pharmaceuticals Inc. (NASDAQ:AGIO) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Wednesday.
According to Zacks, “Agios is a development-stage biopharmaceutical company focused on the development of treatments for cancer and rare genetic metabolic disorders. Being a development-stage company, Agios depends heavily on Celgene for revenues, which it earns in the form of collaboration revenues. The company also depends on Celgene for two of its pipeline candidates – enasidenib and AG-881. Moreover, most of the company's pipeline candidates are in mid- and early-stages of development and thus, quite a few years away from entering the market, if at all. Stiff competition remains a threat as well. Several companies are looking to bring treatments for cancer and rare genetic metabolic disorders by targeting cellular metabolism. However, the company’s metabolic immuno-oncology focused collaboration with Celgene is encouraging. The deal will see Agios receiving funds in the form of upfront, regulatory and commercial milestone payments plus royalties.”
A number of other research firms have also commented on AGIO. Vetr lowered shares of Agios Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $68.42 price target on the stock. in a research report on Tuesday, June 7th. JPMorgan Chase & Co. upgraded shares of Agios Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $50.00 to $62.00 in a research note on Friday, June 10th. Janney Montgomery Scott reiterated a “neutral” rating and set a $47.00 price objective (down from $52.00) on shares of Agios Pharmaceuticals in a research note on Monday, June 13th. Canaccord Genuity reiterated a “hold” rating and set a $50.00 price objective on shares of Agios Pharmaceuticals in a research note on Thursday, June 9th. Finally, Goldman Sachs Group Inc. reiterated a “hold” rating and set a $46.00 price objective on shares of Agios Pharmaceuticals in a research note on Monday, June 13th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $63.44.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/08/agios-pharmaceuticals-inc-agio-lowered-to-sell-at-zacks-investment-research.html
Agios Pharmaceuticals (NASDAQ:AGIO) traded down 2.06% during midday trading on Wednesday, hitting $52.69. 619,050 shares of the company were exchanged. The stock’s market capitalization is $2.00 billion. Agios Pharmaceuticals has a one year low of $33.50 and a one year high of $81.77. The firm’s 50-day moving average price is $46.07 and its 200-day moving average price is $46.30.
Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by $0.99. Agios Pharmaceuticals had a negative return on equity of 47.69% and a negative net margin of 320.33%. The business had revenue of $6.98 million for the quarter, compared to the consensus estimate of $39.62 million. During the same period in the prior year, the business posted ($0.85) earnings per share. Agios Pharmaceuticals’s revenue was down 47.2% compared to the same quarter last year. Equities research analysts anticipate that Agios Pharmaceuticals will post ($5.04) earnings per share for the current year.
In related news, insider Scott Biller sold 5,000 shares of Agios Pharmaceuticals stock in a transaction that occurred on Wednesday, October 5th. The shares were sold at an average price of $55.00, for a total transaction of $275,000.00. Following the sale, the insider now directly owns 48,270 shares in the company, valued at approximately $2,654,850. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Lewis Clayton Jr. Cantley sold 627 shares of Agios Pharmaceuticals stock in a transaction that occurred on Monday, July 25th. The stock was sold at an average price of $41.85, for a total transaction of $26,239.95. Following the sale, the director now owns 112,167 shares in the company, valued at $4,694,188.95. The disclosure for this sale can be found here. Corporate insiders own 10.55% of the company’s stock.
A number of large investors have recently bought and sold shares of AGIO. Wellington Management Group LLP increased its stake in Agios Pharmaceuticals by 0.6% in the first quarter. Wellington Management Group LLP now owns 5,299,078 shares of the biopharmaceutical company’s stock valued at $215,141,000 after buying an additional 31,611 shares in the last quarter. BB Biotech AG increased its stake in Agios Pharmaceuticals by 9.4% in the second quarter. BB Biotech AG now owns 2,363,321 shares of the biopharmaceutical company’s stock valued at $99,011,000 after buying an additional 203,400 shares in the last quarter. Vanguard Group Inc. increased its stake in Agios Pharmaceuticals by 10.1% in the second quarter. Vanguard Group Inc. now owns 2,105,591 shares of the biopharmaceutical company’s stock valued at $88,214,000 after buying an additional 192,852 shares in the last quarter. Flagship Ventures Fund 2007 L.P. acquired a new stake in Agios Pharmaceuticals during the first quarter valued at approximately $78,373,000. Finally, Capital International Investors increased its stake in Agios Pharmaceuticals by 11.4% in the second quarter. Capital International Investors now owns 1,501,037 shares of the biopharmaceutical company’s stock valued at $62,886,000 after buying an additional 153,464 shares in the last quarter. Institutional investors and hedge funds own 81.59% of the company’s stock.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. Its cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.